Page last updated: 2024-08-24

cremophor el and Hematologic Diseases

cremophor el has been researched along with Hematologic Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, YH; Huang, ST; Li, WS; Lin, CT; Wang, YP; Wu, HC	1
Brouwer, E; de Jonge, MJ; Gelderblom, H; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van der Burg, ME; Verweij, J	1
Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J	1

Trials

1 trial(s) available for cremophor el and Hematologic Diseases

Article	Year
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Biological Availability; Female; Gastrointestinal Diseases; Glycerol; Hematologic Diseases; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mesothelioma; Middle Aged; Ovarian Neoplasms; Paclitaxel	2002

Article

Year

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:4

Topics: Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Biological Availability; Female; Gastrointestinal Diseases; Glycerol; Hematologic Diseases; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mesothelioma; Middle Aged; Ovarian Neoplasms; Paclitaxel

2002

Other Studies

2 other study(ies) available for cremophor el and Hematologic Diseases

Article	Year
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol. International journal of oncology, 2018, Volume: 53, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Female; Glycerol; Hematologic Diseases; Humans; Liposomes; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neutropenia; Paclitaxel; Therapeutic Equivalency; Tissue Distribution	2018
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1 Topics: Animals; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Female; Glycerol; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pharmaceutical Vehicles	2002

Article

Year

Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.

International journal of oncology, 2018, Volume: 53, Issue:3

Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Female; Glycerol; Hematologic Diseases; Humans; Liposomes; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neutropenia; Paclitaxel; Therapeutic Equivalency; Tissue Distribution

2018

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1

Topics: Animals; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Female; Glycerol; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pharmaceutical Vehicles

2002